Leaders in Supply & Demand Side Intelligence

Forgot your login?

[X]

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.

E-Mail:
Also, what is 75 + 6?

China's Pharma Companies Face Fiscal Challenges for R&D Projects

Premium Article
China RD pharma 0621
Attachment Included

BEIJING--June 8, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--In the last 10 years, the average return on investment (ROI) in China's pharmaceutical research and development (R&D) market has declined, which creates an obstacle for China's small- and medium-sized developers of patterned drugs.

Read the Complete Article
Details on this Article:
Industry Segment: Pharmaceutical & Biotech
Word Count: 185 Words
Attachment: China RD pharma 0621
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles
Premium News Article
  Key Players in China's CDMO Pharma-Bio Market Push Forward
Premium News Article
  China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies
Premium News Article
  China Authorizes Five Companies to Make COVID-19 Vaccines
Premium News Article
  Real Estate Developers Pour $34 Billion into Global Life Science Building D...
Premium News Article
  China's Pharma Market Could See New Growth Wave as India's Plants Close

PREMIUM ARTICLE

This article is available for Premium Members only.

Subscribe Now! All Fields are Required...


Pricing Help?

All Members Receive the Following Resources:

  • Industry News Digest
  • Upcoming Webinars
  • On-Demand Webinars
  • The NavigatIIR Newsletter
  • Daily Industry News Blog
  • Economic Indicators